These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 37611121)
1. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a Sacher A; LoRusso P; Patel MR; Miller WH; Garralda E; Forster MD; Santoro A; Falcon A; Kim TW; Paz-Ares L; Bowyer S; de Miguel M; Han SW; Krebs MG; Lee JS; Cheng ML; Arbour K; Massarelli E; Choi Y; Shi Z; Mandlekar S; Lin MT; Royer-Joo S; Chang J; Dharia NV; Schutzman JL; Desai J; N Engl J Med; 2023 Aug; 389(8):710-721. PubMed ID: 37611121 [TBL] [Abstract][Full Text] [Related]
2. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Desai J; Alonso G; Kim SH; Cervantes A; Karasic T; Medina L; Shacham-Shmueli E; Cosman R; Falcon A; Gort E; Guren T; Massarelli E; Miller WH; Paz-Ares L; Prenen H; Amatu A; Cremolini C; Kim TW; Moreno V; Ou SI; Passardi A; Sacher A; Santoro A; Stec R; Ulahannan S; Arbour K; Lorusso P; Luo J; Patel MR; Choi Y; Shi Z; Mandlekar S; Lin MT; Royer-Joo S; Chang J; Jun T; Dharia NV; Schutzman JL; ; Han SW Nat Med; 2024 Jan; 30(1):271-278. PubMed ID: 38052910 [TBL] [Abstract][Full Text] [Related]
3. KRAS Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176 [TBL] [Abstract][Full Text] [Related]
4. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329 [TBL] [Abstract][Full Text] [Related]
5. Sotorasib for Lung Cancers with Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690 [TBL] [Abstract][Full Text] [Related]
6. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968 [TBL] [Abstract][Full Text] [Related]
7. Adagrasib in Non-Small-Cell Lung Cancer Harboring a Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005 [TBL] [Abstract][Full Text] [Related]
8. Adagrasib in Advanced Solid Tumors Harboring a Bekaii-Saab TS; Yaeger R; Spira AI; Pelster MS; Sabari JK; Hafez N; Barve M; Velastegui K; Yan X; Shetty A; Der-Torossian H; Pant S J Clin Oncol; 2023 Sep; 41(25):4097-4106. PubMed ID: 37099736 [TBL] [Abstract][Full Text] [Related]
9. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Brazel D; Nagasaka M Target Oncol; 2024 May; 19(3):297-301. PubMed ID: 38739329 [TBL] [Abstract][Full Text] [Related]
10. Garsorasib in patients with KRAS Li Z; Dang X; Huang D; Jin S; Li W; Shi J; Wang X; Zhang Y; Song Z; Zhang J; Zhuang W; Liu X; Jiang L; Meng X; Zhao M; Zhou J; Zhang L; Wang P; Luo H; Yang J; Cang S; Wang X; Zhang L; Lu S; Lancet Respir Med; 2024 Aug; 12(8):589-598. PubMed ID: 38870979 [TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors. Choi Y; Dharia NV; Jun T; Chang J; Royer-Joo S; Yau KK; Assaf ZJ; Aimi J; Sivakumar S; Montesion M; Sacher A; LoRusso P; Desai J; Schutzman JL; Shi Z; Clin Cancer Res; 2024 Sep; 30(17):3788-3797. PubMed ID: 38995268 [TBL] [Abstract][Full Text] [Related]
12. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS Li Z; Song Z; Zhao Y; Wang P; Jiang L; Gong Y; Zhou J; Jian H; Dong X; Zhuang W; Cang S; Yang N; Fang J; Shi J; Lu J; Ma R; Wu P; Zhang Y; Song M; Xu CW; Shi Z; Zhang L; Wang Y; Wang X; Zhang Y; Lu S J Thorac Oncol; 2023 Jul; 18(7):940-951. PubMed ID: 36948246 [TBL] [Abstract][Full Text] [Related]
13. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated Yaeger R; Weiss J; Pelster MS; Spira AI; Barve M; Ou SI; Leal TA; Bekaii-Saab TS; Paweletz CP; Heavey GA; Christensen JG; Velastegui K; Kheoh T; Der-Torossian H; Klempner SJ N Engl J Med; 2023 Jan; 388(1):44-54. PubMed ID: 36546659 [TBL] [Abstract][Full Text] [Related]
14. Acquired Resistance to KRAS Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704 [TBL] [Abstract][Full Text] [Related]
15. Sotorasib in Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS N Engl J Med; 2023 Jan; 388(1):33-43. PubMed ID: 36546651 [TBL] [Abstract][Full Text] [Related]
16. Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation. Wang J; Martin-Romano P; Cassier P; Johnson M; Haura E; Lenox L; Guo Y; Bandyopadhyay N; Russell M; Shearin E; Lauring J; Dahan L Oncologist; 2022 Jul; 27(7):536-e553. PubMed ID: 35325211 [TBL] [Abstract][Full Text] [Related]
17. Sotorasib for previously treated colorectal cancers with KRAS Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824 [TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS Ernst SM; van Marion R; Atmodimedjo PN; de Jonge E; Mathijssen RHJ; Paats MS; de Bruijn P; Koolen SL; von der Thüsen JH; Aerts JGJV; van Schaik RHN; Dubbink HJ; Dingemans AC J Thorac Oncol; 2024 Jul; 19(7):995-1006. PubMed ID: 38615940 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS Hoshiyama H Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617 [TBL] [Abstract][Full Text] [Related]
20. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer. Lee A Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]